« Generics Jihad | Main | Harmed and Dangerous »
August 14, 2006
Beijing Supplemental
by Peter Pitts
In case you’re not a regular reader the China People's Daily, here's an important story with potentially significant implications for DSHEA. Tongjitang Pharmaceutical Co. Ltd. of southwest China's Guizhou Province signed a contract with Synarc, a US professional drug test service provider. Synarc will carry out clinical curative effect test on a traditional Chinese medicine to treat osteoporosis. According to Qi Guomin, an official of Ministry of Health, it is for the first time a Chinese herbal medicine will be tested in line with western clinical curative effect standards. Some of the Chinese traditional medicines have passed the FDA's safety test and been sold as "health food" in western countries, Qi said. The test will be carried out in China under FDA's criteria and the result will be released at some point this year.
Note to Congress: When contemplating FDA reform don't forget the urgent need to reform DSHEA -- it's more than just a stadium in Queens.
Posted by Peter Pitts at August 14, 2006 08:55 AM
Trackback Pings
TrackBack URL for this entry:
/cgi-bin/mt-tb.cgi/9
